Emmaus Life Sciences, Inc. Common Stock
EMMA
EMMA was delisted on the 10th of September, 2019.
7 hedge funds and large institutions have $71K invested in Emmaus Life Sciences, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.
25% less capital invested
Capital invested by funds: $95K → $71K (-$24K)
36% less funds holding
Funds holding: 11 → 7 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$49K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.3K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$3K |
EMMA Hedge Fund Activity: Q1 2019 in Review
7 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Emmaus Life Sciences, Inc. Common Stock (EMMA) for Q1 2019, worth a combined $71K — down 25% from $95K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EMMA and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $49K sold.
- 7 institutional investors held Emmaus Life Sciences, Inc. Common Stock (EMMA) as of Q1 2019, down from 11 in Q4 2018.
- Funds reported $71K of Emmaus Life Sciences, Inc. Common Stock stock for Q1 2019, down 25% quarter-over-quarter.
- 0 funds opened new Emmaus Life Sciences, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of -4 holders.
- The largest Emmaus Life Sciences, Inc. Common Stock seller in Q1 2019 was Citadel Advisors, an estimated $49K sold.
Based on aggregated 13F filings for Q1 2019.